[go: up one dir, main page]

MX2022012034A - Medicamento para el tratamiento del dolor. - Google Patents

Medicamento para el tratamiento del dolor.

Info

Publication number
MX2022012034A
MX2022012034A MX2022012034A MX2022012034A MX2022012034A MX 2022012034 A MX2022012034 A MX 2022012034A MX 2022012034 A MX2022012034 A MX 2022012034A MX 2022012034 A MX2022012034 A MX 2022012034A MX 2022012034 A MX2022012034 A MX 2022012034A
Authority
MX
Mexico
Prior art keywords
pain
pain treatment
treatment drug
drug composition
interstitial cystitis
Prior art date
Application number
MX2022012034A
Other languages
English (en)
Inventor
Hiroyuki Kai
Takayuki Kameyama
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2022012034A publication Critical patent/MX2022012034A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un antagonista del receptor P2X3 y/o P2X2/3 para el tratamiento del dolor neuropático, el dolor nociceptivo, o el dolor visceral, y la cistitis intersticial y/o síndrome de dolor vesical. La composición farmacéutica para el tratamiento y/o la profilaxis del dolor neuropático, el dolor nociceptivo, o el dolor visceral, y la cistitis intersticial y/o el síndrome de dolor vesical, comprende el compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo. (ver Fórmula).
MX2022012034A 2020-04-03 2021-04-02 Medicamento para el tratamiento del dolor. MX2022012034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020067146 2020-04-03
PCT/JP2021/014261 WO2021201261A1 (ja) 2020-04-03 2021-04-02 疼痛治療用医薬

Publications (1)

Publication Number Publication Date
MX2022012034A true MX2022012034A (es) 2022-10-27

Family

ID=77929210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012034A MX2022012034A (es) 2020-04-03 2021-04-02 Medicamento para el tratamiento del dolor.

Country Status (11)

Country Link
US (1) US20230158036A1 (es)
EP (1) EP4129294A4 (es)
JP (1) JPWO2021201261A1 (es)
KR (1) KR20220163399A (es)
CN (1) CN115379843A (es)
AU (1) AU2021249945A1 (es)
BR (1) BR112022018979A2 (es)
CA (1) CA3179359A1 (es)
MX (1) MX2022012034A (es)
TW (1) TW202203929A (es)
WO (1) WO2021201261A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151219A4 (en) * 2020-05-15 2024-05-15 Shionogi & Co., Ltd Impurity production-inhibited drug composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60206164T2 (de) 2001-05-18 2006-06-22 Abbott Laboratories, Abbott Park Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
TW200846002A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
CA2752269C (en) 2009-02-13 2016-08-30 Hiroyuki Kai Novel triazine derivative and pharmaceutical composition comprising the same
US9718790B2 (en) 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
TW201331188A (zh) 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
KR102240821B1 (ko) * 2017-03-13 2021-04-15 광주과학기술원 Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 5-히드록시 피리딘계 화합물 및 이를 포함하는 약학적 조성물
AU2019353424B2 (en) 2018-10-05 2022-12-08 Shionogi & Co., Ltd. Medicine for treating chronic cough

Also Published As

Publication number Publication date
US20230158036A1 (en) 2023-05-25
EP4129294A4 (en) 2024-05-08
BR112022018979A2 (pt) 2022-11-01
TW202203929A (zh) 2022-02-01
WO2021201261A1 (ja) 2021-10-07
JPWO2021201261A1 (es) 2021-10-07
CA3179359A1 (en) 2021-10-07
KR20220163399A (ko) 2022-12-09
AU2021249945A1 (en) 2022-12-15
CN115379843A (zh) 2022-11-22
EP4129294A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
SA521431048B1 (ar) مركبات بيروليدين
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
PH12021500034A1 (en) Compounds useful in hiv therapy
SG11201907240XA (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
SG11201805791RA (en) COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α
PH12021550713A1 (en) Medicament for the treatment of chronic cough
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
MX2022012034A (es) Medicamento para el tratamiento del dolor.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
MX2025001111A (es) Nuevas sulfonamidas y su uso como agentes neuroprotectores y/o neurorrestauradores
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
MX2022001413A (es) Compuesto de pirimidina-5-carboxamida.
EA202193211A1 (ru) Лечение синуклеопатий
EA202190339A1 (ru) Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.